The official blog of the Lung Institute.

Lung Institute Opening Dallas Location in April 2016 to Help Patients with Chronic Lung Diseases

2 Mar 2016
| Under Press, Uncategorized | Posted by | 6 Comments

The Lung Institute, a leading provider of stem cell therapy research for lung diseases, announces new location and the addition of Dr. Marakatham, bringing jobs and alternative options for chronic lung diseases like COPD to the metro Dallas area.

Dallas, Texas – March 3, 2016: The Lung Institute will open a new stem cell research treatment facility in Dallas in April of 2016, providing lung disease patients an alternative option that has reportedly improved patients’ quality of life by an average of 82 percent. Lung disease is the third leading cause of preventable death in the United States, and traditional treatment options remain unchanged over the past 30 years, until now. The Lung Institute is on the frontlines in the fight against lung disease, providing patients with a chance to improve their quality of life using a minimally invasive, outpatient stem cell procedure.

Dr Marakatham - Lung Institute Dallas

“Dallas is a hub for cutting edge medical advancements, so it was a natural fit for the Lung Institute to expand to this part of the country,” said Executive Vice President Ann Miller. “We also found that many patients are traveling from these areas, so the closer we can move to those who need our help, the better able we are to serve them.”

As required by Texas state law, the Dallas clinic has received IRB approval for research protocols and stem cell procedures from an organization dedicated to integrity in human research and fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP). Operating under IRB approval is important because it protects patients in emerging fields of medicine, and ensures that facilities are following proper protocols on both the medical and administrative sides of operation.

If there is one thing I enjoy most about my job, it’s when I hear from patients about how they feel better after treatment.

Sreedevi Marakatham, M.D. will be joining the Lung Institute as medical director of the Dallas clinic. Her specialty is internal medicine and, prior to the Lung Institute, she worked as a primary care physician where she saw many patients who suffer from chronic obstructive pulmonary disease (COPD). “When I heard about the Lung Institute, I was very interested to learn about alternative methods of patient care, especially when we can do something for severe COPD cases; whereas in conventional medicine, we don’t have an answer,” she stated.

“With this stem cell research facility in Dallas,” Marakatham added, “we are going in at a cellular level to help patients. If there is one thing I enjoy most about my job, it’s when I hear from patients about how they feel better after treatment.”

According to the Lung Institute’s recent in house white paper, 84 percent of COPD patients reported an improved quality of life score within three months of receiving treatment at a Lung Institute clinic. Additionally, 48 percent of those tested saw at least a 10 percent increase in pulmonary function, with an average increase of 16 percent. The white paper analysis focused on COPD patients, however the Lung Institute studies how stem cell therapy affects other pulmonary conditions by providing treatment for other diseases such as pulmonary fibrosis, chronic bronchitis, emphysema and interstitial lung disease.

“In my practice I used to see a lot of COPD patients, most prescribed conventional treatment methods like inhalers and steroids, which come with various side effects,” said Marakatham. “In severe cases, patients faced a lung transplant, but not all patients want to proceed with that. This is really a hope for such patients. When I heard about the Lung Institute’s success rate, and how stem cell therapy is really helping patients lead a better life, I was very much interested in joining to be able to truly make a difference in these patients’ lives.”

About the Lung Institute

The Lung Institute is a leading medical provider of regenerative cellular investigative therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. To date the organization has treated over 1,800 patients, 82 percent of which report an improved quality of life. Founded in 2013 in Tampa, Fla., the Lung Institute currently has clinics in Nashville, Tenn., Scottsdale, Ariz., and Pittsburgh, Pa., and now Dallas, Texas. For more information, please visit www.lunginstitute.com/dallas or call (800) 382-8095.

# # #


  1. Matt

    11 months ago

    Hello Sharon,
    Thank you for your question. We recommend you discuss this with your primary care doctor. They will be more familiar with your medical history and can give you a more informed opinion. Thanks again and have a great day.

  2. Sharon grimes

    11 months ago

    Can metals in your mouth from fixed bridges cause lung deteration

  3. PB

    2 years ago

    Hello Michael,

    Thanks for your comment and for your suggestion. We’ll pass your suggestion for a Lung Institute clinic in Los Angeles, California along to the proper people, and we’ll take it into consideration. Please feel free to contact us (855) 313-1149 if you or your father-in-law have any questions regarding stem cell therapy, and we would be happy to answer them.

    Best Regards,

    The Lung Institute

  4. Michael

    2 years ago

    My father in-law needs the lung institute near Los Angeles, CA. Is a location planned for Southern California?

  5. PB

    2 years ago

    Dear Ada,

    We would be happy to discuss stem cell treatment options with you one-on-one. Please feel free to contact us today at (855) 313-1149 to speak with one of our patient coordinators. We look forward to speaking with you soon.

    Best Regards,

    The Lung Institute


    2 years ago

    I spoke with a lady about stem cell treatment on my lung for copd. My name is Ada Kelley I live in Lufkin, tx. She send me and e-mail but I have lost the e-mail. I would love for her to call again.I would like to have cell treatment.

Your Comment

Your email address will not be published.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.